This regulatory milestone positions the Cranbury and Suzhou-based CDMO as a key infrastructure provider in the burgeoning exosome market. Developers utilizing the firm's GMP-compliant platform can now bypass redundant documentation, effectively shortening the timeline from research to clinical trial submissions. The platform supports a variety of cell lines, including HEK293 and iPSC, and offers scalability from 2L to 50L bioreactors. With production capabilities that guarantee exosome concentrations of at least 1E+11 particles per milliliter, Porton Advanced aims to standardize the transition from initial development to commercial-scale manufacturing. The company currently manages 215,000 square feet of specialized facilities, including 12 cell therapy suites, to support global partners in the regenerative medicine sector.
Porton Advanced Gains FDA Recognition for Exosome Cell Bank
The U.S. Food and Drug Administration has accepted a Drug Master File for Porton Advanced's umbilical cord-derived mesenchymal stem cell bank. By securing DMF #32973, the company provides a regulatory shortcut for pharmaceutical sponsors, allowing them to reference established manufacturing data to streamline the approval process for new exosome-based therapies.
Comments (0)
No comments yet. Be the first!